Clinical Trials Browser

Phase 2 × Terminated × Rifaximin × Clear all

NCT04249622 2025-09-16

Rifaximin for the Treatment of Gastrointestinal Toxicities Related to Pertuzumab-Based Therapy in Patients With Stage I-III HER2 Positive Breast Cancer

Phase 2 Terminated

20 enrolled 13 charts

Anatomic Stage I Breast Cancer AJCC v8